These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis. Shah NJ; Shah UN Indian J Ophthalmol; 2011; 59(4):318-9. PubMed ID: 21666322 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461 [TBL] [Abstract][Full Text] [Related]
18. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019 [TBL] [Abstract][Full Text] [Related]
19. Drastic effect of ranibizumab on choroidal neovascularization in idiopathic angioid streaks. Yolcu U; Gundogan FC; Diner O Arq Bras Oftalmol; 2015; 78(4):257-9. PubMed ID: 26375345 [TBL] [Abstract][Full Text] [Related]